TABLE 3

Rates of seroconversion, GMT, and GMFRs following oral vaccination with a single standard dose or high dose of CVD 103-HgR live oral vaccine or two doses (14 days apart) of Shanchol inactivated cholera vaccinea

Days after vaccinationSeroconversionbGMTc (95% CI)GMFRd (95% CI)
CVD 103-HgRShancholCVD 103-HgRShancholCVD 103-HgRShanchol
108 CFU109 CFUAfter 1st doseAfter 2nd dose108 CFU109 CFUAfter 1st doseAfter 2nd dose108 CFU109 CFUAfter 1st doseAfter 2nd dose
No. of participants who seroconverted/total no. tested (%)95% CI (%)No. of participants who seroconverted/total no. tested (%)95% CI (%)No. of participants who seroconverted/total no. tested (%)95% CI (%)No. of participants who seroconverted/total no. tested (%)95% CI (%)
028A (21, 39)28B (21, 38)47C (32, 69)
722/42 (52.4)36.4, 68.027/44D (61.4)45.5, 75.617/46E (37.0)23.2, 52.599 (57, 171)199 (106, 375)102 (65, 160)3.9 (2.4, 6.3)7.4F (3.8, 14.2)2.1G (1.3, 3.4)
1433/46 (71.7)56.5, 84.040/48H (83.3)69.8, 92.528/50I (56.0)41.3, 70.095J (56, 161)214K (117, 394)128 (75, 218)3.3L (2.0, 5.5)7.6M (3.9, 15.1)2.7N (1.5, 4.8)
2136/45 (80.0)65.4, 90.441/46O (89.1)76.4, 96.434/49P (69.4)54.6, 81.773Q (43, 125)168R (97, 291)132 (75, 232)2.8S (1.8, 4.3)6.2T (3.3, 11.5)3.0 (1.6, 5.5)
2836/43 (83.7)69.3, 93.242/47 (89.4)76.9, 96.535/46 (76.1)61.2, 87.475U (46, 123)167V (111, 253)135 (81, 226)2.7W (1.9, 4.0)5.9X (3.7, 9.5)3.0Y (1.8, 5.1)
  • a Seroconversion was considered a ≥4-fold rise in titer over the day 0 baseline titer. The standard dose was ≥2 × 108 CFU, and the high dose was ≥2 × 109 CFU.

  • b D versus E, P = 0.021; H versus I, P = 0.003; O versus P, P = 0.018.

  • c A versus C, P = 0.045; B versus C, P = 0.034; J versus K, P = 0.045; Q versus R, P = 0.031; U versus V, P = 0.014.

  • d F versus G, P = 0.019; L versus M, P = 0.052; M versus N, P = 0.019; S versus T, P = 0.035; W versus X, P = 0.012; X versus Y, P = 0.057.